Fluoropyrimidine/platinum doublet chemotherapy has been recommended as the standard first-line treatment for most patients with AGC and adding trastuzumab is strongly recommended for patients with human epidermal growth factor receptor 2 (HER2)-positive GC. This evidence concerns the gene ERBB2 and gastric cancer.